natgillin/translations-raw huggingface dataset:
Rebif 44 micrograms solution for injection
Rebif 44 mikrograma otopina za injekciju
Rebif 44 micrograms solution for injection in pre-filled pen
Rebif 44 mikrograma otopina za injekciju u napunjenoj brizgalici
Rebif 44 micrograms solution for injection in pre-filled pen Interferon beta-1a
Rebif 44 mikrograma otopina za injekciju u napunjenoj brizgalici interferon beta-1a
Rebif 44 micrograms solution for injection in pre-filled syringe
Rebif 44 mikrograma otopina za injekciju u napunjenoj štrcaljki
Rebif 44 micrograms solution for injection in pre-filled syringe Interferon beta-1a
Rebif 44 mikrograma otopina za injekciju u napunjenoj štrcaljki interferon beta-1a
Rebif 44 micrograms/0.5 mL solution for injection in cartridge
Rebif 44 mikrograma/0,5 ml otopina za injekciju u ulošku
Rebif 44 micrograms/0.5 mL solution for injection in cartridge Interferon beta-1a
Rebif 44 mikrograma/0,5 ml otopina za injekciju u ulošku interferon beta-1a
Rebif 8.8 mcg solution for injection
Rebif 8,8 μg otopina za injekciju
Rebif 8.8 mcg/0.1 mL Rebif 22 mcg/0.25 mL Solution for injection
Rebif 8,8 μg/0,1 ml Rebif 22 μg/0,25 ml otopina za injekciju
Rebif 8.8 micrograms and Rebif 22 micrograms are supplied in an initiation pack that is intended for use during the initial 4 weeks of treatment, during which a gradual increase in Rebif dose is recommended.
Rebif 8,8 mikrograma i Rebif 22 mikrograma dostupni su u pakiranju za početak liječenja koje je namijenjeno za primjenu tijekom početna 4 tjedna liječenja tijekom kojih se preporučuje postupni porast doze lijeka Rebif.
Rebif 8.8 micrograms is a solution for injection in a pre-filled pen for self-administration.
Rebif 8,8 mikrograma otopina za injekciju u napunjenoj brizgalici za samostalnu primjenu.
Rebif 8.8 micrograms is a solution for injection in a pre-filled syringe with a fixed needle for self-administration.
Rebif 8,8 mikrograma otopina za injekciju u napunjenoj štrcaljki s pričvršćenom iglom za samostalnu primjenu.
Rebif 8.8 micrograms solution for injection
Rebif 8,8 mikrograma otopina za injekciju
Rebif 8.8 micrograms solution for injection in pre-filled pen Interferon beta-1a
Rebif 8,8 mikrograma otopina za injekciju u napunjenoj brizgalici interferon beta-1a
Rebif 8.8 micrograms solution for injection in pre-filled pen Rebif 22 micrograms solution for injection in pre-filled pen
Rebif 8,8 mikrograma otopina za injekciju u napunjenoj brizgalici Rebif 22 mikrograma otopina za injekciju u napunjenoj brizgalici
Rebif 8.8 micrograms solution for injection in pre-filled pen Rebif 22 micrograms solution for injection in pre-filled pen Interferon beta-1a
Rebif 8,8 mikrograma otopina za injekciju u napunjenoj brizgalici Rebif 22 mikrograma otopina za injekciju u napunjenoj brizgalici interferon beta-1a
Rebif 8.8 micrograms solution for injection in pre-filled syringe Rebif 22 micrograms solution for injection in pre-filled syringe
Rebif 8,8 mikrograma otopina za injekciju u napunjenoj štrcaljki Rebif 22 mikrograma otopina za injekciju u napunjenoj štrcaljki
Rebif 8.8 micrograms solution for injection in pre-filled syringe Rebif 22 micrograms solution for injection in pre-filled syringe Interferon beta-1a
Rebif 8,8 mikrograma otopina za injekciju u napunjenoj štrcaljki Rebif 22 mikrograma otopina za injekciju u napunjenoj štrcaljki interferon beta-1a
Rebif 8.8 micrograms solution for injection Interferon beta-1a
Rebif 8,8 mikrograma otopina za injekciju interferon beta-1a
Rebif 8.8 micrograms/0.1 mL solution for injection in cartridge Rebif 22 micrograms/0.25 mL solution for injection in cartridge
Rebif 8,8 mikrograma/0,1 ml otopina za injekciju u ulošku Rebif 22 mikrograma/0,25 ml otopina za injekciju u ulošku
Rebif 8.8 micrograms/0.1 mL solution for injection in cartridge Rebif 22 micrograms/0.25 mL solution for injection in cartridge Interferon beta-1a
Rebif 8,8 mikrograma/0,1 ml otopina za injekciju u ulošku Rebif 22 mikrograma/0,25 ml otopina za injekciju u ulošku interferon beta-1a
Rebif contains 1.0 mg benzyl alcohol per dose of 0.2 mL and 2.5 mg benzyl alcohol per dose of
Rebif sadrži 1,0 mg benzilnog alkohola po dozi od 0,2 ml i 2,5 mg benzilnog alkohola po dozi od
Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in these patients.
Rebif još nije istražen u bolesnika s primarnom progresivnom multiplom sklerozom te ga ne treba koristiti u tih bolesnika.
Rebif is available in packs of 1, 3 and 12 pre-filled syringes.
Rebif je dostupan u pakiranjima od 1, 3 i 12 napunjenih štrcaljki.
Rebif is given by injection under the skin (subcutaneously) using a pre-filled pen called “RebiDose”.
Rebif se daje injekcijom pod kožu (potkožno) primjenom napunjene brizgalice „RebiDose“.
Rebif is given by injection under the skin (subcutaneously).
Rebif se daje injekcijom pod kožu (potkožno).
Rebif is intended for subcutaneous (under the skin) injection.
Rebif je namijenjen za potkožno (pod kožu) injiciranje.
Rebif is not recommended for use in children below 2 years of age.
Primjena Rebifa ne preporuèuje se kod djece mlađe od 2 godine.
Rebif should only be used under the supervision of your doctor.
Rebif se treba koristiti samo pod nadzorom Vašeg liječnika.
RebiSmart is programmed to guide you through the entire initiation process and automatically increases the dose during the initiation period.
RebiSmart je programiran da Vas navodi kroz cijeli proces inicijacije i automatski povećava dozu tijekom razdoblja inicijacije.
Rebound insomnia and anxiety
Povratna (eng. rebound) nesanica i tjeskoba
Rebounders
Povratak na početno
Rebounders Never suppressed subjects
Ispitanici u kojih nikada nije bilo supresije
Reboxetine:
Reboksetin:
Recap the pen.
Vratite zatvarač na brizgalicu.
recap the pre-filled pen or put fingers into the yellow safety guard.
vraćati zatvarač na napunjenu brizgalicu ili stavljati prste u žuti sigurnosni štitnik.
Recapping is not required.
Nije potrebno vraćati zatvarač.
Received 3 doses
Primilo 3 doze
receiving concomitant treatment
istodobno liječe lijekom Kaletra
receiving digoxin should
koji primaju digoksin treba
recent (< 10 days) prolonged and vigorous external heart massage
nedavna (<10 dana) produžena i intenzivna vanjska masaža srca
Recent biopsy, major trauma
nedavna biopsija ili velika trauma
recent bleeding in your brain (intracranial or intracerebral bleeding)
nedavno krvarenje u mozak (intrakranijalno ili intracerebralno krvarenje)
Recent clinical studies with patients treated up to three years with AVONEX suggest that approximately 5% to 8% develop neutralising antibodies.
Nedavna klinička ispitivanja, tijekom kojih su se kroz tri godine bolesnici liječili AVONEXOM ukazuju na razvoj neutralizirajućih protutijela u približno 5% do 8% bolesnika.
recent completed neurosurgical or ophthalmological procedures, concomitant use of medicinal products affecting haemostasis.
nedavno obavljeni neurokirurški ili oftalmološki zahvati istodobno uzimanje lijekova koji utječu na hemostazu
recent completed neurosurgical or ophthalmological procedures, concomitant use of medicinal products affecting haemostasis.
nedavno obavljeni neurokirurški ili oftalmološki zahvati, istodobno uzimanje lijekova koji utječu na hemostazu.
recent gastrointestinal or genitourinary bleeding (within 10 days)
nedavno gastrointestinalno ili genitourinarno krvarenje (u zadnjih 10 dana)
Recent gastrointestinal or genitourinary bleeding (within the past 10 days)
nedavno gastrointestinalno ili genitourinarno krvarenje (u proteklih 10 dana)
recent history of inflammation of the membrane that forms the lining of the abdominal (tummy) cavity (peritonitis) low levels of albumin (a protein) in your blood
nedavna upala sluznice koja obavija trbušnu šupljinu (peritonitis) niske razine albumina (proteina) u krvi.
recent history of stroke or myocardial infarction (within the last 6 months), unstable angina and known hereditary retinal degenerative disorders such as retinitis pigmentosa.
nedavno preboljeli moždani udar ili infarkt miokarda (u prethodnih 6 mjeseci), nestabilna angina i poznati nasljedni degenerativni poremećaji mrežnice, poput retinitis pigmentosa.
recent history of stroke or myocardial infarction (within the last 6 months), unstable angina, and known hereditary retinal degenerative disorders such as retinitis pigmentosa.
nedavno preboljeli moždani udar ili infarkt miokarda (u prethodnih 6 mjeseci), nestabilna angina i poznati nasljedni degenerativni poremećaji mrežnice, poput retinitis pigmentosa.
recent history of stroke or myocardial infarction (within the last 6 months), unstable angina, and known hereditary retinal degenerative disorders such as retinitis pigmentosa.
nedavno preboljen moždani udar ili infarkt miokarda (u prethodnih 6 mjeseci), nestabilna angina i poznati nasljedni degenerativni poremećaji mrežnice, poput retinitis pigmentosa.
recent ischemic stroke,
nedavni ishemijski moždani udar
recent ischemic stroke,
nedavni ishemijski moždani udar,
recent major stomach or bowel surgery
nedavni veliki kirurški zahvat na želucu ili crijevima
Recent marketing of the veterinary medicinal product
Nedavne prodaje veterinarsko medicinskog proizvoda,
recent myocardial infarction,
nedavni infarkt miokarda,
recent myocardial infarction, shock.
nedavni infarkt miokarda, šok.
Recent or latent infection with field myxoma virus seems to play a role in this to a certain extent.
Čini se da u tome do određene mjere imaju ulogu nedavne ili latentne infekcije terenskim miksoma virusom.
Recent or ongoing clinically significant gastrointestinal disorder
Nedavni ili trenutačni klinički značajni poremećaj probavnog sustava
recent or recurrent bleeding from the stomach or intestines (e.g. a stomach ulcer or colon polyps) body weight of less than 60 kg.
ako ste nedavno krvarili iz želuca ili crijeva ili često imate takva krvarenja (npr. želučani vrijed ili crijevne polipe) ako Vam je tjelesna težina manja od 60 kg.
recent surgery (including dental work, ask your dentist about this)
nedavne operacije (uključujući i zahvate kod zubara, upitajte o tome svog zubara)
recent surgery (including some dental procedures)
ako ste nedavno imali operaciju (uključujući i neke stomatološke zahvate)
recent surgery on the brain, spine or eye
nedavnu operaciju na mozgu, kralježnici ili oku
Recent treatment with medicinal products known to prolong the QTc interval that may still be circulating at the time that Eurartesim is commenced (e.g. mefloquine, halofantrine, lumefantrine, chloroquine, quinine and other antimalarial medicinal products) taking into account their elimination half-life.
Nedavno liječenje lijekovima za koje se zna da produljuju QTc interval i koji još uvijek mogu biti prisutni u krvotoku u vrijeme kad se započne s Eurartesimom (npr. meflokin, halofantrin, lumefantrin, klorokin, kinin i drugi antimalarici) s obzirom na njihov poluvijek eliminacije.
Recent use of these medicines might increase the risk of Aerivio Spiromax affecting your adrenal glands.
Nedavna primjena ovih lijekova može povećati rizik od utjecaja Aerivio Spiromaxa na Vaše nadbubrežne žlijezde.
Recent use of these medicines might increase the risk of Aerivio Spiromax affecting your adrenal glands.
Nedavna primjena ovih lijekova može povećati rizik od utjecaja Airexar Spiromaxa na Vaše nadbubrežne žlijezde.
recently had a stroke within the last 6 months.
ako ste u posljednjih 6 mjeseci pretrpjeli moždani udar.
recently suffered a head injury or brain disease
ako ste nedavno zadobili ozljedu glave ili imali bolest mozga
Recently treated animals should not be handled until the application site is dry
Nedavno tretirane životinje ne dirati dok se mjesto aplikacije ne osuši.
Recently treated animals should not be handled until the application site is dry.
Nedavno tretirane životinje ne treba dirati dok se mjesto aplikacije ne osuši.
Recently, hydroxycarbamide has shown to be associated with the generation of nitric oxide suggesting that nitric oxide stimulates cyclic guanosine monophosphatase (cGMP) production, which then activates a protein kinase and increases the production of HbF.
Nedavno je primijećeno da je hidroksikarbamid povezan sa nastankom dušikova oksida pri čemu dušikov oksid stimulira stvaranje cikličke gvanozin monofosfataze (cGMP) koja zatim aktivira protein-kinazu i potiče stvaranje HbF.
Receptors for somatostatin can be found in high amounts on tumour cells, including tumours of the pituitary gland which cause Cushing’s disease and acromegaly.
Receptori za somatostatin nalaze se u velikim količinama na tumorskim stanicama, uključujući i tumore hipofize, što uzrokuje Cushingovu bolest i akromegaliju.
recFSH 150 IU
rekFSH 150 IU
recFSH 200 IU
rekFSH 200 IU
recFSH 300 IU
rekFSH 300 IU
Recheck the prescribed medication amount.
Ponovno provjerite koja je propisana količina lijeka.
Recipients of allogeneic PBPCs mobilised with filgrastim
Primatelji alogenih progenitorskih stanica iz periferne krvi mobiliziranih filgrastimom
Recocam 20 mg/ml solution for injection for cattle, pigs and horses
Recocam 20 mg/ml otopina za injekciju za goveda, svinje i konje
Recocam 20 mg/ml solution for injection for cattle, pigs and horses meloxicam
Recocam 20 mg/ml otopina za injekciju za goveda, svinje i konje meloksikam
Recognition and treatment of severe immune-mediated reaction, including anaphylaxis.
Prepoznavanje i liječenje teške, imunološki posredovane reakcije, uključujući anafilaksiju.
Recognition of signs and symptoms of severe hypoglycaemia and the appropriate actions to take
prepoznavanje znakova i simptoma teške hipoglikemije te odgovarajuće mjere koje treba poduzeti
Recognition of signs and symptoms of under or no delivery of insulin and the appropriate actions to take
prepoznavanje znakova i simptoma primjene premale doze ili prestanka primjene inzulina te odgovarajuće mjere koje treba poduzeti
recombinant
Purevax FeLV
Recombinant cholera toxin B subunit (rCTB) 1 mg.
Rekombinantna B podjedinica toksina kolere (rCTB) 1 mg.
Recombinant coagulation factor VIII (octocog alfa)
rekombinantni koagulacijski faktor VIII (oktokog alfa)
Recombinant coagulation factor VIII (octocog alfa) Intravenous use.
rekombinantni koagulacijski faktor VIII (oktokog alfa) Primjena u venu.
Recombinant FSH is biochemically very similar to urinary human FSH and is distributed, metabolised, and excreted in the same way.
Rekombinantni FSH biokemijski je vrlo sličan ljudskom urinarnom FHS pa se distribuira, metabolizira i izlučuje na isti način.
recombinant human chorionic gonadotropin, r-hCG produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology
rekombinantni humani korionski gonadotropin, r-hCG proizveden na stanicama jajnika kineskog hrčka (CHO) tehnologijom rekombinantne DNK.
recombinant human follicle stimulating hormone (r-hFSH) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
rekombinantni ljudski folikulostimulirajući hormon (r-hFSH), proizveden u stanicama jajnika kineskog hrčka (CHO) tehnologijom rekombinantne DNK.
Recombinant human hyaluronidase (rHuPH20)
Rekombinantna ljudska hijaluronidaza (rHuPH20)
Recombinant human hyaluronidase (rHuPH20) vial
Bočica s rekombinantnom ljudskom hijaluronidazom (rHuPH20)
Recombinant human hyaluronidase (rHuPH20) vial Sodium chloride
Bočica s rekombinantnom ljudskom hijaluronidazom (rHuPH20) natrijev klorid
Recombinant human hyaluronidase is a purified glycoprotein of 447 amino acids produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
Rekombinantna ljudska hijaluronidaza je pročišćeni glikoprotein koji sadrži 447 aminokiselina, a proizvedena je tehnologijom rekombinantne DNK na stanicama ovarija kineskog hrčka (CHO).
Recombinant human hyaluronidase is a soluble recombinant form of human hyaluronidase that increases the permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan.
Rekombinantna ljudska hijaluronidaza je topivi rekombinantni oblik ljudske hijaluronidaze koji pojačava propusnost potkožnog tkiva privremeno depolimerizirajući hijaluronan.
Recombinant interferon beta-1b* 250 microgram (8.0 million IU) per ml when reconstituted.
Nakon rekonstitucije, jedan ml sadrži 250 mikrograma (8,0 milijuna IU) rekombinantnog interferona beta-1b .
Recombinant interferon beta-1b* 250 microgram (8.0 million IU) per ml when reconstituted.
Nakon rekonstitucije, jedan ml sadrži 250 mikrograma (8,0 milijuna IU) rekombinantnog interferona beta-1b.
recombinant murine/human chimeric monoclonal antibody directed against the interleukin-2 receptor -chain (CD25 antigen) produced in a mouse myeloma cell line by recombinant DNA technology.
rekombinantno mišje/ljudsko kimerično monoklonsko protutijelo usmjereno protiv interleukin-2 receptora -lanca (CD25 antigen) proizvedeno u mišjoj staničnoj liniji mijeloma koristeći tehnologiju rekombinantne DNK.
Recombinant Neisseria meningitidis group B NHBA/NadA/fHbp proteins
rekombinantne proteine NHBA/NadA/fHbp iz Neisseria meningitidis grupe B
Recombinant Protein Q from L. infantum MON-1
Rekombinirana bjelančevina Q iz L. infantum MON-1
Recombinant Protein Q from Leishmania infantum MON-1 ≥ 36.7 ELISA Units (EU)*
Rekombinirana bjelančevina Q iz Leishmania infantum MON-1 ≥ 36,7 ELISA jedinica (EU)
Recombinant Protein Q from Leishmania infantum MON-1 ≥ 36.7 EU
Rekombinirana bjelančevina Q iz Leishmania infantum MON-1 ≥ 36,7 EU
Recombinant Protein Q from Leishmania infantum MON-1: ≥ 36.7 ELISA units (EU)*
Rekombinirana bjelančevina Q iz Leishmania infantum MON-1 : ≥ 36,7 ELISA jedinica (EU)
Recombinant viruses showing ≥ 3- fold resistance to tipranavir grow at less than 1% of the rate detected for wild type HIV-1 in the same conditions.
Rekombinantni virusi koji pokazuju ≥ 3-struku rezistenciju na tipranavir rastu stopom koja iznosi manje od 1% stope rasta divljeg tipa HIV-1 u istim uvjetima.
Recommendation
Preporuke za istodobnu
recommendation can be
Ne može se dati posebna
recommendation can be
preporuka za doziranje.
Recommendation concerning co- administration
Preporuke za istodobnu primjenu
Recommendation concerning co- administration with ZEPATIER
Preporuke za istodobnu primjenu s lijekom ZEPATIER
Recommendation concerning co-administration with 245 mg tenofovir disoproxil (as fumarate)
Preporuka o istovremenoj primjeni s 245 mg tenofovirdizoproksila (u obliku tenofovirdizoproksilfumarata)
Recommendation concerning co-administration with Atripla (efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg)
Preporuka za istovremenu primjenu s Atriplom (efavirenz 600 mg, emtricitabin 200 mg, tenofovirdizoproksil fumarat 300 mg)
Recommendation concerning co-administration with cobicistat 150 mg and atazanavir or darunavir
Preporuka za istovremenu primjenu uz kobicistat od 150 mg i atazanavir ili darunavir
Recommendation concerning co-administration with efavirenz
Istodobna primjena simeprevira s
Recommendation concerning co-administration with efavirenz
Istodobnu primjenu atovakona/progvanilklorida s efavirenzom treba izbjegavati kad god je to moguće.
Recommendation concerning co-administration with efavirenz
lijekova nisu ustanovljene značajne
Recommendation concerning co-administration with efavirenz
primjena efavirenza s lijekovima
Recommendation concerning co-administration with efavirenz
primjenjuje s efavirenzom.
Recommendation concerning co-administration with efavirenz
razmotriti primjena alternative
Recommendation concerning co-administration with Harvoni
Ne preporučuje se njihova istovremena primjena.
Recommendation concerning co-administration with Lojuxta
Preporuke za istodobnu primjenu s Lojuxtom
Recommendation concerning co-administration with Stribild
Preporuka za istovremenu primjenu sa Stribildom
Recommendation concerning co-administration with Truvada (emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg)
Preporuka za istovremenu primjenu s Truvadom (emtricitabin 200 mg, tenofovirdizoproksilfumarat 300 mg)
Recommendation for a 3-hour on-site observation period post injection
Preporuku za 3-satno razdoblje opservacije na mjestu davanja lijeka nakon injekcije
Recommendation for appropriate monitoring until the event resolves if an event should occur
Preporuku za odgovarajući nadzor dok događaj ne prestane, ako se pojavi
Recommendation for co- administration
Preporuka za istovremenu primjenu
Recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should be vigilant for signs and symptoms of a post injection syndrome event, and should be able to obtain assistance if needed
Preporuku o informiranju bolesnika da ostatak dana nakon injekcije ne bi trebali voziti ni upravljati strojevima, da bi trebali paziti na znakove i simptome postinjekcijskog sindroma te bi trebali moći pribaviti pomoć ako bude potrebno
Recommendation for kidney function measurement
Preporuke za mjerenje bubrežne funkcije
Recommendation for overnight monitoring after the first dose (or if the first dose monitoring applies during treatment re-initiation)
Preporuka za praćenje preko noći nakon prve doze (ili ako se primjenjuje praćenje prve doze tijekom ponovnog započinjanja liječenja)
Recommendation for patients not to drive while receiving BLINCYTO
Preporuku za bolesnike da ne upravljaju vozilima tijekom liječenja lijekom BLINCYTO.
Recommendation for patients not to drive while receiving BLINCYTO and to contact immediately the treating physician if they experience neurological symptoms
Preporuka za bolesnike da ne upravljaju vozilima tijekom liječenja lijekom BLINCYTO i da odmah obavijeste svog liječnika ako osjete neurološke simptome.
Recommendation for patients not to drive while receiving BLINCYTO and to contact immediately the treating physician/nurse if they experience neurological symptoms
Preporuku za bolesnike da ne upravljaju vozilima tijekom liječenja lijekom BLINCYTO i da odmah obavijeste svog liječnika/medicinsku sestru ako osjete neurološke simptome.
Recommendation for re-initiation of GILENYA therapy after treatment interruption The same first dose monitoring as for treatment initiation is recommended when:
Preporuka za ponovno započinjanje terapije GILENYOM nakon prekida liječenja Isti oblik praćenja prve doze kao i kod početka liječenja preporučuje se ako se:
RECOMMENDATION FOR THE SAFE HANDLING
PREPORUKA ZA SIGURNO RUKOVANJE
Recommendation regarding accidental exposure of IMLYGIC to HCPs:
Preporuke za zdravstvene radnike vezane uz slučajno izlaganje lijeku IMLYGIC;
Recommendation regarding the accidental transmission of IMLYGIC from patient to close contacts or HCPs:
Preporuke vezane uz slučajan prijenos lijeka IMLYGIC iz bolesnika na osobe u neposrednoj blizini ili zdravstvene radnike;
Recommendation regarding the accidental transmission of IMLYGIC from patient to close contacts or HCPs:
Preporuke vezane uz slučajan prijenos lijeka IMLYGIC sa bolesnika na osobe u neposrednoj blizini ili zdravstvene radnike;
Recommendation that the 3-hour observation period should be extended as clinically appropriate for patients who exhibit any signs or symptoms consistent with olanzapine overdose
Preporuku da se 3-satno razdoblje promatranja produlji prema kliničkoj potrebi u onih bolesnika koji pokazuju bilo kakve znakove ili simptome koji odgovaraju predoziranju olanzapinom
Recommendation that, immediately prior to a patient leaving the health care facility, it should be confirmed that the patient is alert, oriented, and absent of any signs or symptoms of overdose
Preporuku da se neposredno prije otpusta bolesnika iz zdravstvene ustanove mora potvrditi da je bolesnik priseban, orijentiran i da nema znakova ni simptoma predoziranja
Recommendation to consider discontinuing ponatinib if a complete haematologic response has not occurred by 3 months (90 days).
Preporuka za razmatranje prekida davanja ponatiniba ako se potpuni hematološki odgovor ne javi za 3 mjeseca (90 dana).
Recommendation to monitor patients for signs and symptoms of neurotoxicity
Preporuka da se bolesnika prati radi znakova i simptoma neurotoksičnosti.
Recommendations
Pre poruke